AMAR - Amarillo Biosciences Inc - Oral Interferon Development

Investor Relations: Philippe Niemetz

PAN Consultants, Ltd. Tel: 800-477-7570

Tel: 212-344-6464 Fax: 212-618-1276

Joseph M. Cummins, DVM, PhD
Amarillo Biosciences, Inc.

Tel: 806-376-1741 x 13 Fax: 806-376-9301

Amarillo Biosciences Appoints Kimball Miller, MD as Medical Director

Amarillo, Texas January 16, 2008 — Amarillo Biosciences, Inc. (OTCBB: AMAR) today announced that it had appointed Kimball Miller, MD its Medical Director. Dr. Miller will assist the Company with all its human clinical trials; including the human influenza studies that will be conducted in Australia and the USA .

Kimball Austin Miller, MD, MSHA is an academic, medical clinician, health care administrator, management consultant and primary care provider with more than 20 years’ experience in clinical practices ranging from small adolescent groups to the Mayo Clinic. Dr. Miller has served in academic faculty positions in several medical and business schools, as a medical director of clinical sections in large multispecialty practices, as an administrator of a physician-hospital organization, as well as the chief medical officer of a multistate provider sponsored HMO.

“Dr. Kimball Miller will aid Amarillo Biosciences in its human clinical trials and consult with us as to the best possible means to insure that our studies are conducted in the most efficient manner possible,” said Dr. Joseph M. Cummins, President and CEO, ABI. “With Dr. Miller’s contribution, we expect to accelerate the process of obtaining FDA approval for our low-dose oral interferon.”

About Amarillo Biosciences, Inc.
Amarillo Biosciences, Inc. is a U.S. biotechnology firm operating in global partnership with the Hayashibara Group, which also holds 12% of Amarillo Biosciences’ shares and has provided over $18 million in loans, grants and equity investments. The company's primary focus is extensive and ongoing R&D into the use of low-dose, orally administered interferon as a treatment for a variety of conditions, including Sjogren's syndrome, Behcet’s disease, and opportunistic infections in patients who are HIV positive. In its 23-year history, the company has invested nearly $38 million to establish oral interferon as a therapeutic agent. The majority of those funds were invested in clinical trials in an effort to achieve FDA approval for interferon. Additional information is available at http://www.amarbio.com/.

Except for the historical information contained herein, the matters discussed in this news release are forward-looking statements that involve risks and uncertainties, including uncertainties related to product development, uncertainties related to the need for regulatory and other government approvals, dependence on proprietary technology, uncertainty of market acceptance of oral interferon or the Company’s other product candidates and other risks detailed from time to time in the Company’s filings with the Securities and Exchange Commission. In particular, see “Item 1. Description of Business” of the Company’s Form 10-KSB for the year ended December 31, 2006. --END--